DUBLIN, Sept. 17, 2024 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) today announced the closing of a registered public offering by Perrigo Finance Unlimited Company, an indirect wholly-owned finance subsidiary of Perrigo (the "Issuer"), of $715 million aggregate principal amount of the Issuer's 6.125% Senior Notes due 2032 (the "USD Notes") and €350 million aggregate principal amount of the Issuer's 5.375% Senior Notes due 2032 (the "Euro Notes" and together with the USD Not ...

DUBLIN, Sept. 12, 2024 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) today announced the pricing of a registered public offering by Perrigo Finance Unlimited Company, an indirect wholly-owned finance subsidiary of Perrigo (the "Issuer"), of $715 million aggregate principal amount of the Issuer's 6.125% Senior Notes due 2032 (the "USD Notes") and €350 million aggregate principal amount of the Issuer's 5.375% Senior Notes due 2032 (the "Euro Notes" and together with the USD Not ...

Atkinson joins Perrigo from Haleon plc, where he previously served as Interim General CounselDUBLIN, Sept. 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. He is a skilled lawyer with nearly 25 years of experience, mostly within the regulated consumer self-care industry.President and CEO Patrick Lockwood-Taylor commented, "I am ver ...

DUBLIN, Aug. 27, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Piper Sandler Growth Frontiers Conference on Tuesday, September 10 at 10:00 AM CDT. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.About PerrigoPerrigo Company plc (NYSE: PRGO) is a leading provider of ...

DUBLIN, Aug. 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer. In this newly created position, Dr. Ball will be responsible for an enterprise-wide marketing strategy that incorporates deep understanding of consumer needs and translates those into winning brand strategies, tactics, and actions. He will also evaluate untapped mark ...

财务数据和关键指标变化 - 第二季度有机销售额下降9.1%,其中来自婴儿配方奶粉的负面影响约7个百分点,上呼吸道和无痛睡眠辅助品类销售下降4个百分点,其他业务增长1.7个百分点 [29] - 毛利率和营业利润率同比分别扩大190和160个基点,环比扩大超过400个基点 [30] - 第二季度每股收益为0.53美元,较上年同期下降0.10美元,主要由于上年同期有0.09美元的税收优惠以及婴儿配方奶粉业务的负面影响0.14美元 [31] - 年初至今有机销售额下降8.1%,其中婴儿配方奶粉负面影响5.3个百分点,上呼吸道和无痛睡眠辅助品类下降4.4个百分点,其他业务增长1.6个百分点 [54] - 年初至今调整后营业利润下降近10%,剔除婴儿配方奶粉影响则增长近17% [54] - 年初至今每股收益下降0.25美元或23%,包括婴儿配方奶粉影响0.43美元和上年税收优惠0.09美元 [54] 各条业务线数据和关键指标变化 - CSCI业务第二季度有机增长1%,上呼吸道和无痛睡眠辅助品类下降3.5个百分点,其他业务增长4.5个百分点,主要来自Compeed、ellaOne和Paranix等品牌的市场份额提升以及英国店品牌业务高单位数增长 [55] - CSCA业务第二季度有机销售下降15%,其中婴儿配方奶粉下降10.8个百分点,上呼吸道和无痛睡眠辅助品类下降4.4个百分点,最后一批SKU优化导致下降1.8个百分点,其他业务持平,但OTC品牌如Opill、Nasonex和Mederma增长超过40% [56] 各个市场数据和关键指标变化 - 第二季度全球季节性需求下降中高个位数,美国零售客户库存水平变化导致咳嗽/感冒和过敏产品销售下降 [23][33] - 公司在与一家美国客户的谈判中,放弃了部分利润率过低的业务,导致2024年销售额下降1.5个百分点,但预计2025年将通过新业务获取完全抵消 [25][72][73][75] 公司战略和发展方向及行业竞争 - 公司正在优化婴儿配方奶粉生产网络,提高生产效率,预计下半年业绩将大幅改善 [36][41][42][43][44][45][46][47] - Opill产品在美国市场销售持续增长,公司正在分析消费者意识、试用转化率和重复使用情况,以优化营销策略 [37][88][89][90] - 公司正在加强品牌建设能力,并寻求更多增长机会,预计将在2025年及以后带来回报 [13][14][48] - 公司正在执行成本节约和效率提升计划,包括HRA协同效应、供应链优化和Project Energize,预计到2026年将实现1.4亿美元至1.7亿美元的税前年度总成本节约 [38][39][40] - 公司正在优化美国店品牌业务,提高利润率,并预计2025年将通过新业务获取完全抵消2024年放弃的部分业务 [25][72][73][75] 管理层对经营环境和未来前景的评论 - 管理层对婴儿配方奶粉业务的恢复充满信心,预计下半年业绩将大幅改善 [22][36][41][42][43][44][45][46][47] - 管理层对公司多元化业务模式表示乐观,能够抵御季节性需求波动的影响 [23][24][33][98] - 管理层对公司未来增长机会充满信心,正在加强品牌建设和人才引进,预计将在2025年及以后带来回报 [13][14][16][48][100][101][102] 其他重要信息 - 公司已完成HRA Rare Diseases业务的出售,并收到2.05亿美元的前期收益 [60] - 公司预计2024年全年经营现金流转换率为90%至100% [61] - 公司预计2024年末净负债率约为3.8倍至4倍 [62] - 公司维持2024年每股收益2.50美元至2.65美元的指引,下半年每股收益有望超过上半年一倍 [66][68][69] 问答环节重要的提问和回答 问题1 **Chris Schott 提问** 询问公司放弃的美国店品牌业务的具体情况,以及新获得的业务与之前放弃的业务相比利润率情况 [72][73][75] **Patrick Lockwood-Taylor 和 Eduardo Bezerra 回答** - 放弃的业务利润率较低,是一次性事件 - 公司新获得的业务利润率更高,预计2025年将完全抵消2024年放弃业务带来的销售额下降 [73][75] 问题2 **Korinne Wolfmeyer 提问** 询问公司是否还会有进一步的SKU精简,以及对2025年业绩的影响 [81][82][84][85][86][87] **Eduardo Bezerra 回答** - 此次SKU精简已经在计划之内 - 公司预计2025年婴儿配方奶粉业务的负面影响将得到大幅改善 - 同时也在关注消费需求和感冒季节性的变化对业绩的影响 [85][86][87] 问题3 **Daniel Biolsi 提问** 询问公司是否会减少羟亲麻黄碱产品的库存,以及婴儿配方奶粉的供给和库存情况 [93][94][95][96][97][98] **Patrick Lockwood-Taylor 和 Eduardo Bezerra 回答** - 公司目前没有减少羟亲麻黄碱产品库存的计划,因为仍有较好的市场需求 [96] - 公司正在努力提高婴儿配方奶粉的产能和供给,预计2025年上半年将开始建立安全库存 [94

Perrigo Company plc (PRGO) reported adjusted earnings of 53 cents per share in the second quarter of 2024, beating the Zacks Consensus Estimate of 48 cents. Earnings were down 15.9% year over year due to discrete tax benefits of nine cents per share in the year-ago period and a negative financial impact of 14 cents from infant formula.Net sales declined 10.7% year over year to $1.07 billion, missing the Zacks Consensus Estimate of $1.13 billion. The downside was due to lower net sales of infant formula and ...

Perrigo (PRGO) reported $1.07 billion in revenue for the quarter ended June 2024, representing a year-over-year decline of 10.7%. EPS of $0.53 for the same period compares to $0.63 a year ago.The reported revenue represents a surprise of -5.79% over the Zacks Consensus Estimate of $1.13 billion. With the consensus EPS estimate being $0.48, the EPS surprise was +10.42%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

film costed tablet. Ulpristal sol 3 Contraceptiv ishe ene teblet of the same fine every dow taxus S @ UNGI Putcass Projects Dupp 24 (2188111 VETATILITO: POI (2) "excell" and the " 126 Gentle SEVENTARY 81 DHLAPE TABING DIS ON 20 200000 • AFFECTIVE PAIN RELASE 16 CAPSINES NOUROLANG Company to Advit PUN RELIEVER/FEVER REDUCER (NSAID) 80151 21/1237/41 (16)/1330) 1990 1990 vir sceers SI STORE yourbrand esomeprazole magnesium Perrigo Q2/2024 Earnings Presentation – 8/2/24 Bradley Joseph VP Investor Relations & Co ...

Perrigo (PRGO) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.42%. A quarter ago, it was expected that this drug company would post earnings of $0.24 per share when it actually produced earnings of $0.29, delivering a surprise of 20.83%.Over the last four quarters, the company has ...